Literature DB >> 26646445

Elevated level of serum glycoprotein bifucosylation and prognostic value in Chinese breast cancer.

Linling Ju1, Yanping Wang1, Qing Xie1, Xiukun Xu2, Yong Li3, Zijun Chen4, Yunsen Li5.   

Abstract

Aberrant glycosylation is highly associated with cancer progression. The aim of this study was to compare bifucosylated N-glycans in sera obtained from healthy controls and breast cancer patients, with the goal of identifying a potential indicator for monitoring the recurrence and metastasis of breast cancer. A unique structural pattern of bifucosylated N-glycan, with both core and antennary fucosylation, was identified in breast cancer patients. The spectrum of antennary fucosylation was a composite of the standard spectra of Lewis X and H2, indicating a mixture of the two epitopes. Permethylated N-glycans of the glycoproteins extracted from 91 breast cancer patients and 43 healthy controls were detected using linear ion-trap quadrupole-electrospray ionization mass spectrometry, which appeared to be a highly sensitive and useful approach in the detection and identification of N-glycans. To evaluate MS profile data, several statistical tools were applied, including Student'st-test, partial least squares discriminant analysis and receiver-operating characteristic curve. The results showed that the measurement of bifucosylation degree and CEA levels had an improved diagnostic performance compared with that of CEA alone. We compared the potential of bifucosylated N-glycan as an indicator of breast cancer recurrence with the current clinical biomarkers, i.e., CEA, CA 15-3 and CA125. The result revealed that, compared with CEA, CA 15-3 and CA125, the bifucosylation degree of N-glycans could be a more reliable indicator of breast cancer recurrence.
© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  N-glycan; bifucosylation; breast cancer; mass spectrometry

Mesh:

Substances:

Year:  2015        PMID: 26646445     DOI: 10.1093/glycob/cwv117

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  7 in total

Review 1.  Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer.

Authors:  Muchena J Kailemia; Gege Xu; Maurice Wong; Qiongyu Li; Elisha Goonatilleke; Frank Leon; Carlito B Lebrilla
Journal:  Anal Chem       Date:  2017-10-31       Impact factor: 6.986

2.  Serum IgA1 shows increased levels of α2,6-linked sialic acid in breast cancer.

Authors:  Hannah J Lomax-Browne; Claire Robertson; Aristotelis Antonopoulos; Anthony J C Leathem; Stuart M Haslam; Anne Dell; Miriam V Dwek
Journal:  Interface Focus       Date:  2019-02-15       Impact factor: 3.906

Review 3.  Quantitative clinical glycomics strategies: A guide for selecting the best analysis approach.

Authors:  Milani W Patabandige; Leah D Pfeifer; Hanna T Nguyen; Heather Desaire
Journal:  Mass Spectrom Rev       Date:  2021-02-10       Impact factor: 9.011

4.  Rapid N-Glycan Profiling of Serum and Plasma by a Novel Slide-Based Imaging Mass Spectrometry Workflow.

Authors:  Calvin R K Blaschke; Alyson P Black; Anand S Mehta; Peggi M Angel; Richard R Drake
Journal:  J Am Soc Mass Spectrom       Date:  2020-08-18       Impact factor: 3.109

5.  Clinical Assay for the Early Detection of Colorectal Cancer Using Mass Spectrometric Wheat Germ Agglutinin Multiple Reaction Monitoring.

Authors:  I-Jung Tsai; Emily Chia-Yu Su; I-Lin Tsai; Ching-Yu Lin
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

6.  Abberant Immunoglobulin G Glycosylation in Rheumatoid Arthritis by LTQ-ESI-MS.

Authors:  Zhipeng Su; Qing Xie; Yanping Wang; Yunsen Li
Journal:  Int J Mol Sci       Date:  2020-03-17       Impact factor: 5.923

Review 7.  Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers.

Authors:  Veronika Gajdosova; Lenka Lorencova; Peter Kasak; Jan Tkac
Journal:  Sensors (Basel)       Date:  2020-07-20       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.